These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
Unprofitable clinical-stage biotechs have lost their appeal in the past year, given the challenging economic and market conditions we still haven't entirely left behind. That's why companies such as Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics (NASDAQ: NTLA) are down massively over the trailing 12-month period.
However, Wall Street expects both to bounce back. The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119% for the latter as of this writing.
Can these biotechs meet these expectations, or is Wall Street too optimistic? Let's find out.
Source Fool.com